Furthermore, hemizygous loss of Aα occurs recurrently (42%) in prostate adenocarcinomas, and hemizygous loss of Aα occurs more frequently (greater than 75%) in metastatic disease (40). This evidence concerns the gene TEAD1 and metastatic neoplasm.